BANGKOK, Oct 22, 2024 - (ACN Newswire) - T.MAN Pharmaceutical PCL (SET: TMAN), a leader in the production and distribution of pharmaceuticals and healthcare products in Thailand for over 50 years, debuts on the Stock Exchange of Thailand (SET) under the Personal Products & Pharmaceuticals sector. The company has showcased its commitment to investing in technology to enhance production and efficiency, focusing on the research, development, and innovation of pharmaceuticals and healthcare products. Aiming to expand its market presence both domestically and internationally, the company strives to be a leader in health innovation that enhances the quality of life for all.

Mr. Prapon Thanachotipan, Chief Executive Officer of T.MAN Pharmaceutical PCL ("the company" or "TMAN"), announces that the company starts trading its shares on the SET on October 22, 2024, under the consumer products industry group, specifically in the personal products and pharmaceuticals category, using the ticker symbol “TMAN”. He expresses confidence that the company’s strong foundation in health innovation, from research and development of pharmaceuticals and healthcare products to enhancing production standards with modern technology and effective marketing strategies, will make TMAN a quality stock that attracts investors. The company aims to be a leader in health innovation, helping to improve the quality of life for everyone.

Following its listing, the company has allocated a short-to-medium-term investment budget not exceeding 777.5 million THB, divided as follows:

1) Ongoing projects involving construction and machinery installation, totaling up to 298.5 million THB. These include:

1.1) Projects to improve the efficiency of herbal product manufacturing,

1.2) Projects to enhance the efficiency of modern medicine production,

1.3) Expansion of research and development,

1.4) Increased production capacity for dietary supplements,

1.5) Development of sales systems using information technology,

1.6) Procurement of quality control equipment for modern medicine,

1.7) Procurement of quality control equipment for dietary supplements, and

1.8) Construction of warehouses and office buildings, with several projects already underway.

2) The company has also planned future investments for business expansion in 5 projects, with a budget not exceeding 479.0 million THB. These include:

2.1) Construction of a new headquarters building,

2.2) The first phase of expanding production capacity for modern medicine,

2.3) Investment in the installation of solar panels (Solar Rooftop),

2.4) Upgrading production areas for modern medicine, and

2.5) The second phase of expanding production capacity for modern medicine.

Click here to continue